Healthy adults
Conditions
Interventions
Panelists will apply BSL5-170327C on their full face twice a day for 3 weeks, and then cleanse with launched product followed by placebo toner twice a day for 2 weeks.
Panelists will apply BSL5-170327
Sponsors
Kao Corporation
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Panelists who are Japanese males ranging from 20-49 years old.
Exclusion criteria
Exclusion criteria: -Panelists with illnesses or diseases which in the opinion of the investigators, might interfere with the conduct of the study or the interpretation of results. Especially panelists with any skin irritation, skin condition (such as rosacea, eczema, atopic dermatitis, or psoriasis), or severe acne on their faces. -Panelists who take any supplements, OTC or prescription medications, especially anti-inflammation agents, anti-bacterial agents, analgesic agents, hormonal agents, laxative agents, intestinal agents, etc. -Panelists under the care of a doctor taking prescription medication (topical) for any facial skin issues. -Panelists who have used any pore strips within 2 weeks of the first visit. -Panelists who tend to have noticeable beard and whisker hair within 1 day after shaving. -Panelists with allergy or sensitivity to any facial care product, facial moisturizer, facial cleanser, pore strip, or to any specific ingredient or fragrance used in these types of products. -Panelists who cannot refrain from sun exposure, tanning beds, sunless tanners, pore strips, and skin lightening products until the study completes. -Panelists who cannot refrain from facial cleansing and shaving on the days of evaluation visits. -Panelists currently participating in, or scheduled to participate in, another facial study during the study period. -Panelists having any conditions which in the opinion of the investigators, might interfere with the conduct of the study or the interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the dermatological assessment, sebum composition, gene expressions, skin moisture content, and transepidermal water loss before and after the application of BSL5-170327C, as well as the continuous applications of both BSL5-170327C and BSL5-170327S. | — |
Countries
Japan
Contacts
Public ContactNaoki Oya
Kao Corporation Biological Science Research
Outcome results
None listed